-
CLSA is bullish on these two pharma stocks
Most pharma companies provided a broad roadmap on the transition to complex generic products while maintaining a calibrated R&D allocation strategy
-
Should you buy, sell or hold Dr Reddy’s post sharp fall?
The pharma major reported a consolidated profit of Rs 570.8 crore for the quarter ended June 2021, 1.5% down from the year-ago period
-
Dr Reddy’s Q4 profit dips 29% to Rs 557 crore
For 2020-21 fiscal year, Dr Reddy's posted a consolidated net profit of Rs 1,952 crore as against Rs 2,026 crore in 2019-20
